SinSa Labs

SinSa Labs is a clinical-stage biotechnology company specializing in the development of bioengineered antibiotics and ophthalmic therapeutics. The company utilizes its proprietary 'Spearhead antibiotics' platform to design small molecules and synthetic peptides that exploit biochemical weaknesses in bacterial membranes, aiming to overcome multi-drug resistance in pathogens such as A. baumannii and CRE. In addition to its anti-infective pipeline, SinSa Labs maintains a significant strategic presence in the ophthalmology sector through a long-term collaboration with Santen Pharmaceutical and the Singapore Eye Research Institute (SERI). This partnership, known as the SONIC (Santen-SERI Open Innovation Center) initiative, focuses on developing disease-modifying therapies for vision-threatening conditions including glaucoma, myopia, and diabetic retinopathy.